PAAP 2025 Conference Unites Addiction Professionals for Collaborative Change
September 8, 2025 — PAAP's 2025 Annual Conference unites addiction professionals for collaborative care strategies, CE credits, and networking on Sept 18 in PA & virtual.
NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
September 8, 2025 — PAAP's 2025 Annual Conference unites addiction professionals for collaborative care strategies, CE credits, and networking on Sept 18 in PA & virtual.
September 7, 2025 — AI voice agents help older adults accurately report blood pressure readings, improving hypertension management and reducing healthcare costs by 88.7% in new study.
September 7, 2025 — Study reveals children with high blood pressure at age 7 face 40-50% higher risk of early cardiovascular death. Learn why childhood screening matters for lifelong heart health.
September 6, 2025 — Asana Orthodontics in Albany offers wellness-focused care with clear aligners, early intervention, and advanced technology. Led by Dr. Nourah Abdul Kader, providing personalized treatment.
September 6, 2025 — Baxdrostat Phase 2 trial shows 5% blood pressure reduction and 55% less urine albumin in chronic kidney disease patients. Novel aldosterone inhibitor may delay kidney disease progression.
September 5, 2025 — Helix BioPharma cancels GEM financing deal, seeks alternative funding for cancer drug development. TSX:HBP updates strategic capital approach for oncology pipeline advancement.
September 5, 2025 — HealthLynked completes reverse stock split while expanding AI healthcare platform and telemedicine services. Strategic move strengthens capital structure and supports potential uplisting opportunities.
September 5, 2025 — Nursa, founded by Curtis Anderson, revolutionizes healthcare staffing with digital platform connecting 400,000+ nurses to 3,400+ facilities. Solving nursing shortage crisis through technology.
September 5, 2025 — NCI halts funding for pediatric brain cancer trials after 26 years, shifting focus to broader oncology research. CNS Pharmaceuticals becomes crucial for childhood cancer treatment development.
September 5, 2025 — HealthLynked completes reverse stock split to strengthen market position while expanding AI healthcare platform and telemedicine services for improved patient care coordination and cost savings.
September 5, 2025 — Shala Hormone Health launches NOURISH², a dual-action prebiotic and enzyme blend for gut health and nutrient absorption. Available at shala.com for $34.99.
September 4, 2025 — Study shows 48% rise in hypertensive kidney disease deaths over 25 years, with Black individuals facing triple the mortality rate. Urgent call for better BP management.
September 4, 2025 — Study reveals less than 6% of Americans use salt substitutes despite proven benefits for hypertension management. Research presented at AHA Hypertension Sessions shows major public health opportunity.
September 4, 2025 — Devonshire at Erickson Senior Living enhances senior wellness with personalized fitness programs led by experts, offering classes and state-of-the-art facilities for active aging.
September 4, 2025 — Brook.ai's remote care platform helps rural clinics achieve HEDIS quality measures, secure incentives, and improve patient outcomes through AI and human support.
September 4, 2025 — Clene's CNM-Au8 shows improved mitochondrial function & reduced inflammation in Parkinson's disease models. Breakthrough neuroprotective therapy potential for millions affected.
September 4, 2025 — Dr. Callum Potts leads CCRM Miami's fertility clinic with personal IVF experience. Comprehensive care includes IVF, egg freezing & genetic testing all under one roof in Aventura.
September 4, 2025 — Soligenix announces ebolavirus vaccines with ThermoVax platform remain potent after 2 years at 40°C, enhancing global distribution and pandemic readiness.
September 4, 2025 — Oncotelic Therapeutics updates pipeline under CEO Dr. Vuong Trieu, inventor of $2.9B Abraxane cancer drug. Clinical-stage biopharma targeting high-unmet-need cancers.
September 4, 2025 — Soligenix receives FDA orphan drug designation for dusquetide treating Behçet's disease following successful phase 2a trial results showing efficacy and safety.